Customé/ .0002-00 Attorney Docket

IN THE UNITED STATES PATENT AND TRADEMARK OFF

In re Application of:

Hiroshi TAKEMOTO et al.

Group Art Unit: Not Yet Ass

Application No.: 10/048,008

Examiner: Not Yet Assigned

Int'l. Filing Date: July 24, 2000

§ 371 Date: January 25, 2002

PHARMACEUTICAL COMPOSITIONS

**EXHIBITING THROMBOPOIETIN** 

RECEPTOR AGONISM

Commissioner for Patents Washington, DC 20231

Sir:

## TRANSMITTAL LETTER

Enclosed is a Preliminary Amendment. The claims are calculated below:

After Amendment	.	Highest Number Previously Paid	Present Extra			Fee
87	-	39	48	x \$ 18	\$	864
10		4	6	x \$ 84		504
Indep. 10 - 4 - +\$280						
					\$	1368
Reduction by ½ if small entity					-	
TOTAL					\$	1368
- r -	10	10 -	10 - 4 resentation of Multiple Dep. Claim(s)	10 - 4 6 resentation of Multiple Dep. Claim(s)	10 - 4 6 x \$ 84  resentation of Multiple Dep. Claim(s) +\$280  Subtotal  Reduction by ½ if small entity	10 - 4 6 x \$ 84

A fee of \$1,368.00 to cover the cost of the additional claims added by this reply is  $\boxtimes$ enclosed.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Dated: August 9, 2002

Mark J. Feldstein

Reg. No. 46,693

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER 止

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

Attorney Docket No

Group Art Unit: Not yet assigned

Examiner: Not yet assigned

IN THE UNITED STATES PATENT AND TRADEMARK (

In re Application of:

Hiroshi TAKEMOTO et al.

Application No.: 10/048,008

Int'l Filing Date: July 24, 2000

§ 371 Date: January 25, 2002

**PHARMACEUTICAL** For:

COMPOSITIONS EXHIBITING THROMBOPOIETIN RECEPTOR

**AGONISM** 

Commissioner for Patents

Washington, DC 20231

Sir:

## PRELIMINARY AMENDMENT

Prior to the examination of this application, please amend the claims as follows:

## IN THE CLAIMS:

Please cancel claims 1-33, without prejudice or disclaimer, and add new claims 34-76, as follows:

A method of agonizing the thrombopoietin receptor in a subject which comprises administering to said subject a compound represented by the formula (I):

(I)

FINNEGAN

1300 I Street, NW Washington, DC 20005 202.408.4000

www.finnegan.com08/12/2002 TGEDAHU1 00000038 10048008

504.00 OP 864.00 OP